Post by
besttobe on Aug 23, 2021 6:12pm
Organic growth 3% Q3/Q2/FCF breakeven/Loss op's $(1.5mil )
Organic growth calculation
Q2 revenue 24.24 mil
Mayhew .50 mil
Med supply .25 mil
Semo Drug .25 mil
Oxygen Plus .07 mil
Total 25.31 mil
Actual Q3 26.24 mil
Diff .93 mil
Or 3% Q/Q or 12% annualized.
CC will be key, as Q was as expected but miss on analyist EPS before FV adjustments/aquisition expenses and FCF targets. . .
Comment by
Moemoney42 on Aug 23, 2021 11:34pm
Also which is nice is the one time charges that will not appear is subsequent quarters for the costs to acquire the Nasdaq listing.. those associated funds will now go to the bottom line... ;-)
Comment by
lscfa on Aug 25, 2021 1:24pm
So what. A roll-up strategy with no organic growth (industry not growing, share of industry not growing) still increases shareholder value because cost synergies (removal of duplicate expenses) grows the bottom line.
Comment by
gibbonsj on Aug 27, 2021 1:48am
I'm beginning to think that you are one of B2B's aliases.